Advertisement

International Journal of Hematology

, Volume 98, Issue 4, pp 437–445 | Cite as

WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group

  • Hirozumi Sano
  • Akira Shimada
  • Ken Tabuchi
  • Tomohiko Taki
  • Chisato Murata
  • Myoung-ja Park
  • Kentaro Ohki
  • Manabu Sotomatsu
  • Souichi Adachi
  • Akio Tawa
  • Ryoji Kobayashi
  • Keizo Horibe
  • Masahiro Tsuchida
  • Ryoji Hanada
  • Ichiro Tsukimoto
  • Yasuhide HayashiEmail author
Original Article

Abstract

Mutations in Wilms tumor 1 (WT1) have been reported in 10–22 % of patients with cytogenetically normal acute myeloid leukemia (CN-AML), but the prognostic implications of these abnormalities have not been clarified in either adults or children. One hundred and fifty-seven pediatric AML patients were analyzed for WT1 mutations around hotspots at exons 7 and 9; however, amplification of the WT1 gene by the reverse transcriptase-polymerase chain reaction was not completed in four cases (2.5 %). Of the 153 evaluable patients, 10 patients (6.5 %) had a mutation in WT1. The incidence of WT1 mutations was significantly higher in CN-AML than in others (15.2 vs. 4.5 %, respectively, P = 0.03). Of the 10 WT1-mutated cases, eight (80 %) had mutations in other genes, including FLT3-ITD in two cases, FLT3-D835 mutation in two, KIT mutation in three, MLL-PTD in three, NRAS mutation in one, and KRAS mutation in two (in some cases, more than one additional gene was mutated). The incidences of KIT and FLT3-D835 mutations were significantly higher in patients with than in those without WT1 mutation. No significant differences were observed in the 3-year overall survival and disease-free survival; however, the presence of WT1 mutation was related to a poor prognosis in patients with CN-AML, excluding those with FLT3-ITD and those younger than 3 years.

Keywords

Acute myeloid leukemia WT1 mutation Cytogenetically normal acute myeloid leukemia Prognosis 

Notes

Acknowledgments

This work was supported by a grant for Cancer Research and a grant for Research on Children and Families from the Ministry of Health, Labor, and Welfare of Japan, a Grant-in-Aid for Scientific Research (B, C) and Exploratory Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and by a Research grant for Gunma Prefectural Hospitals.

Conflict of interest

There is no conflict of interest.

References

  1. 1.
    Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19:2130–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, et al. Long term results in children with AML: NOPHO-AML Study Group—report of three consecutive trials. Leukemia. 2005;19:2090–100.PubMedCrossRefGoogle Scholar
  3. 3.
    Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499–506.PubMedCrossRefGoogle Scholar
  4. 4.
    Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, et al. Outcomes in CCG-2961, a children’s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children’s oncology group. Blood. 2008;111:1044–53.PubMedCrossRefGoogle Scholar
  5. 5.
    Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007–13.PubMedCrossRefGoogle Scholar
  6. 6.
    Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML 02 multicentre trial. Lancet Oncol. 2010;11:543–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome of AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92:2322–33.PubMedGoogle Scholar
  8. 8.
    Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109:431–48.PubMedCrossRefGoogle Scholar
  9. 9.
    Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2007;25:3337–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell. 1990;60:509–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007;21:868–76.PubMedGoogle Scholar
  12. 12.
    Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms’ tumor. Cell. 1990;61:1257–69.PubMedCrossRefGoogle Scholar
  13. 13.
    Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007;9:1–17.PubMedCrossRefGoogle Scholar
  14. 14.
    Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87:2878–84.PubMedGoogle Scholar
  15. 15.
    Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood. 2006;107:3303–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, Maharry K, et al. Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2008;26:4595–602.PubMedCrossRefGoogle Scholar
  17. 17.
    Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, et al. Mutation of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2008;26:5429–35.PubMedCrossRefGoogle Scholar
  18. 18.
    Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood. 2009;113:4505–11.PubMedCrossRefGoogle Scholar
  19. 19.
    Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood. 2009;113:5951–60.PubMedCrossRefGoogle Scholar
  20. 20.
    Summers K, Stevens J, Kakkas I, Smith M, Smith LL, Macdougall F, et al. Wilms’ tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia. 2007;21:550–1.PubMedCrossRefGoogle Scholar
  21. 21.
    Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children’s Oncology Group. Blood. 2010;116:702–10.PubMedCrossRefGoogle Scholar
  22. 22.
    Staffas A, Kanduri M, Hovland R, Rosenquist R, Ommen HB, Abrahamsson J, et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood. 2011;118:5905–13.PubMedCrossRefGoogle Scholar
  23. 23.
    Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): A study of the Japanese Childhood AML Cooperative Study Group. Blood. 2006;107:1806–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Kobayashi R, Tawa A, Hanada R, Horibe K, Tsuchida M, Tsukimoto I. Extramedullary infiltration at diagnosis and prognosis in children with acute myeloid leukemia. Pediatr Blood Cancer. 2007;48:393–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Shimada A, Taki T, Tabuchi K, Taketani T, Hanada R, Tawa A, et al. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group. Pediatr Blood Cancer. 2008;50:264–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Xu F, Taki T, Yang HW, Hanada R, Hongo T, Ohnishi H, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol. 1999;105:155–62.PubMedCrossRefGoogle Scholar
  27. 27.
    Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, Hanada R, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 2004;103:1085–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Sano H, Shimada A, Taki T, Murata C, Park MJ, Sotomatsu M, et al. RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2012;95:509–15.PubMedCrossRefGoogle Scholar
  29. 29.
    Shimada A, Taki T, Koga D, Tabuchi K, Tawa A, Hanada R, et al. High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group. Int J Hematol. 2012;96:469–76.PubMedCrossRefGoogle Scholar
  30. 30.
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1957;53:457–81.CrossRefGoogle Scholar
  31. 31.
    Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436–40.PubMedCrossRefGoogle Scholar
  32. 32.
    Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;368:753–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA. 1994;91:11045–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008;22:915–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Willasch AM, Gruhn B, Coliva T, Kalinova M, Schneider G, Kreyenberg H, et al. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia. 2009;23:1472–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Østergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients—results from a single-centre study. Br J Haematol. 2004;125:590–600.PubMedCrossRefGoogle Scholar
  37. 37.
    Noronha SA, Farrar JE, Alonzo TA, Gerbing RB, Lacayo NJ, Dahl GV, et al. WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2009;53:1136–9.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  • Hirozumi Sano
    • 1
    • 7
  • Akira Shimada
    • 1
    • 2
  • Ken Tabuchi
    • 3
  • Tomohiko Taki
    • 4
  • Chisato Murata
    • 1
  • Myoung-ja Park
    • 1
  • Kentaro Ohki
    • 1
  • Manabu Sotomatsu
    • 1
  • Souichi Adachi
    • 5
  • Akio Tawa
    • 6
  • Ryoji Kobayashi
    • 7
  • Keizo Horibe
    • 8
  • Masahiro Tsuchida
    • 9
  • Ryoji Hanada
    • 10
  • Ichiro Tsukimoto
    • 11
  • Yasuhide Hayashi
    • 1
    Email author
  1. 1.Department of Hematology/OncologyGunma Children’s Medical CenterShibukawaJapan
  2. 2.Department of Pediatrics/Pediatric Hematology & OncologyOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  3. 3.Department of HematologyKanagawa Children’s Medical CenterYokohamaJapan
  4. 4.Department of Molecular Diagnostics and TherapeuticsKyoto Prefectural University of Medicine, Graduate School of Medical ScienceKyotoJapan
  5. 5.Department of Human Health Sciences, Graduate School of MedicineKyoto UniversityKyotoJapan
  6. 6.Department of PediatricsNational Hospital Organization Osaka National HospitalOsakaJapan
  7. 7.Department of PediatricsSapporo Hokuyu HospitalSapporoJapan
  8. 8.Clinical Research CenterNational Hospital Organization Nagoya Medical CenterNagoyaJapan
  9. 9.Department of PediatricsIbaraki Children’s HospitalMitoJapan
  10. 10.Division of Hematology/OncologySaitama Children’s Medical CenterSaitamaJapan
  11. 11.First Department of PediatricsToho University School of MedicineTokyoJapan

Personalised recommendations